Table 1.

Number of patients in TED13751 study per cohort and dose level

	Cohorts	Dose levels
Escalation cohorts	Main escalation Q2W (n=31)	5 mg/m2 (n=2) 10 mg/m2 (n=4) 20 mg/m2 (n=1) 40 mg/m2 (n=3) 80 mg/m2 (n=3) 100 mg/m2 (n=6) 120 mg/m2 (n=9) 150 mg/m2 (n=3)
	Escalation Q2W with loading dose at cycle 1 followed by 100 mg/m2 Q2W (n=28)	120 mg/m2 (n=3) 135 mg/m2 (n=4) 150 mg/m2 (n=8) 170 mg/m2 (n=13)
	Escalation Q3W (n=15)	120 mg/m2 (n=9) 150 mg/m2 (n=3) 170 mg/m2 (n=6) 190 mg/m2 (n=3)
Expansion cohorts	Colorectal cancer (n=46)	100 mg/m2 Q2W (n=180)
	Gastric carcinoma (n=16)
	Non-squamous non-small cell lung cancer (NSCLC), high CEACAM5 expressors (CEACAM5 target expression ≥2+ in intensity in at least 50% of the tumor cell population, n=64)
	Non-squamous NSCLC, low CEACAM5 expressors (CEACAM5 target expression ≥2+ in intensity in between ≥1% and <50% of the tumor cell population, n=28)
	Small cell lung cancer (SCLC, n=26)